Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis

Arrowhead Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. both aim to bring their first wholly owned drugs to market for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), with Ionis’s olezarsen in the leading position. But Arrowhead outlined a new plan to focus all of its late-stage cardiovascular disease development efforts on its FCS and SHTG drug plozasiran, which means the company will seek a partner to pursue Phase III development of its other late-stage cardiovascular candidate, zodasiran.

Pasadena, CA-based Arrowhead outlined its Phase III program for plozasiran and revealed its partnering plan for zodasiran during a cardiometabolic...